Novel radiopharmaceuticals in cardiovascular medicine: present and future

Basit Iqbal, Geoffrey Currie, Lacey Greene, Hosen Kiat

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Advancements in molecular medicine technology have allowed the development of innovative and better radiopharmaceuticals to augment or replace the existing ones, allowing the acquisition of higher-quality and detailed diagnostic information and accuracy. They build on the strengths of the existing radiotracers or remove their shortcomings, thus bringing them closer to the ideal. Given the discovery of more novel molecules, it is now possible that processes in the human body indicative of predisease stage can be imaged, allowing for appropriate interventions earlier-preventing the development of late stage disease, preventing morbidity and mortality, and reducing the burden on the national health care system. Both positron emission tomography and single-photon emission computed tomography are developing in the fields of perfusion, metabolic, and innervation imaging of the heart. Newer radiotracers can yield higher-quality images with a greater diagnostic potential that are more convenient to use in the daily practice, and at a lower cost. In addition, tracers have been developed for imaging processes like cardiac apoptosis, angiogenesis, and the development of coronary atherosclerosis, enabling physicians to minimize the pathological changes at the reversible stage by promoting appropriate lifestyle changes and pharmaceutical interventions. In this article, we overview the most promising radiotracers that in the future have the potential to become established imaging agents in the field of cardiac nuclear medicine.
Original languageEnglish
Pages (from-to)423-434
Number of pages12
JournalJournal of Medical Imaging and Radiation Sciences
Volume45
Issue number4
DOIs
Publication statusPublished - Dec 2014

Fingerprint

Molecular Medicine
Radiopharmaceuticals
Nuclear Medicine
Single-Photon Emission-Computed Tomography
Human Body
Positron-Emission Tomography
Life Style
Coronary Artery Disease
Perfusion
Medicine
Apoptosis
Technology
Morbidity
Delivery of Health Care
Physicians
Costs and Cost Analysis
Mortality
Pharmaceutical Preparations

Cite this

@article{d333ddc8fa4a4a88a81a2f72d3007d0e,
title = "Novel radiopharmaceuticals in cardiovascular medicine: present and future",
abstract = "Advancements in molecular medicine technology have allowed the development of innovative and better radiopharmaceuticals to augment or replace the existing ones, allowing the acquisition of higher-quality and detailed diagnostic information and accuracy. They build on the strengths of the existing radiotracers or remove their shortcomings, thus bringing them closer to the ideal. Given the discovery of more novel molecules, it is now possible that processes in the human body indicative of predisease stage can be imaged, allowing for appropriate interventions earlier-preventing the development of late stage disease, preventing morbidity and mortality, and reducing the burden on the national health care system. Both positron emission tomography and single-photon emission computed tomography are developing in the fields of perfusion, metabolic, and innervation imaging of the heart. Newer radiotracers can yield higher-quality images with a greater diagnostic potential that are more convenient to use in the daily practice, and at a lower cost. In addition, tracers have been developed for imaging processes like cardiac apoptosis, angiogenesis, and the development of coronary atherosclerosis, enabling physicians to minimize the pathological changes at the reversible stage by promoting appropriate lifestyle changes and pharmaceutical interventions. In this article, we overview the most promising radiotracers that in the future have the potential to become established imaging agents in the field of cardiac nuclear medicine.",
keywords = "Myocardial, Nuclear cardiology, PET cardiac radiotracers, Perfusion, SPECT, Scintigraphy",
author = "Basit Iqbal and Geoffrey Currie and Lacey Greene and Hosen Kiat",
note = "Imported on 12 Apr 2017 - DigiTool details were: month (773h) = December; Journal title (773t) = Journal of Medical Imaging and Radiation Sciences. ISSNs: 1939-8654;",
year = "2014",
month = "12",
doi = "10.1016/j.jmir.2014.09.001",
language = "English",
volume = "45",
pages = "423--434",
journal = "Journal of Medical Imaging and Radiation Sciences",
issn = "1876-7982",
publisher = "Elsevier",
number = "4",

}

Novel radiopharmaceuticals in cardiovascular medicine : present and future. / Iqbal, Basit; Currie, Geoffrey; Greene, Lacey; Kiat, Hosen.

In: Journal of Medical Imaging and Radiation Sciences, Vol. 45, No. 4, 12.2014, p. 423-434.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel radiopharmaceuticals in cardiovascular medicine

T2 - present and future

AU - Iqbal, Basit

AU - Currie, Geoffrey

AU - Greene, Lacey

AU - Kiat, Hosen

N1 - Imported on 12 Apr 2017 - DigiTool details were: month (773h) = December; Journal title (773t) = Journal of Medical Imaging and Radiation Sciences. ISSNs: 1939-8654;

PY - 2014/12

Y1 - 2014/12

N2 - Advancements in molecular medicine technology have allowed the development of innovative and better radiopharmaceuticals to augment or replace the existing ones, allowing the acquisition of higher-quality and detailed diagnostic information and accuracy. They build on the strengths of the existing radiotracers or remove their shortcomings, thus bringing them closer to the ideal. Given the discovery of more novel molecules, it is now possible that processes in the human body indicative of predisease stage can be imaged, allowing for appropriate interventions earlier-preventing the development of late stage disease, preventing morbidity and mortality, and reducing the burden on the national health care system. Both positron emission tomography and single-photon emission computed tomography are developing in the fields of perfusion, metabolic, and innervation imaging of the heart. Newer radiotracers can yield higher-quality images with a greater diagnostic potential that are more convenient to use in the daily practice, and at a lower cost. In addition, tracers have been developed for imaging processes like cardiac apoptosis, angiogenesis, and the development of coronary atherosclerosis, enabling physicians to minimize the pathological changes at the reversible stage by promoting appropriate lifestyle changes and pharmaceutical interventions. In this article, we overview the most promising radiotracers that in the future have the potential to become established imaging agents in the field of cardiac nuclear medicine.

AB - Advancements in molecular medicine technology have allowed the development of innovative and better radiopharmaceuticals to augment or replace the existing ones, allowing the acquisition of higher-quality and detailed diagnostic information and accuracy. They build on the strengths of the existing radiotracers or remove their shortcomings, thus bringing them closer to the ideal. Given the discovery of more novel molecules, it is now possible that processes in the human body indicative of predisease stage can be imaged, allowing for appropriate interventions earlier-preventing the development of late stage disease, preventing morbidity and mortality, and reducing the burden on the national health care system. Both positron emission tomography and single-photon emission computed tomography are developing in the fields of perfusion, metabolic, and innervation imaging of the heart. Newer radiotracers can yield higher-quality images with a greater diagnostic potential that are more convenient to use in the daily practice, and at a lower cost. In addition, tracers have been developed for imaging processes like cardiac apoptosis, angiogenesis, and the development of coronary atherosclerosis, enabling physicians to minimize the pathological changes at the reversible stage by promoting appropriate lifestyle changes and pharmaceutical interventions. In this article, we overview the most promising radiotracers that in the future have the potential to become established imaging agents in the field of cardiac nuclear medicine.

KW - Myocardial

KW - Nuclear cardiology

KW - PET cardiac radiotracers

KW - Perfusion

KW - SPECT

KW - Scintigraphy

U2 - 10.1016/j.jmir.2014.09.001

DO - 10.1016/j.jmir.2014.09.001

M3 - Article

C2 - 31051915

VL - 45

SP - 423

EP - 434

JO - Journal of Medical Imaging and Radiation Sciences

JF - Journal of Medical Imaging and Radiation Sciences

SN - 1876-7982

IS - 4

ER -